BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, deadly condition. Although risk stratification is extremely important for assessment of prognosis and to guide therapy, there is lack of evidence concerning the role of novel biomarkers. In a pivotal study, we sought to comparatively investigate the predictive power of several new biomarkers in PAH. METHODS: Patients with prevalent PAH were enrolled in the study protocol, which included clinical, functional and echocardiographic assessment. Blood samples were collected at baseline for determination of NT-proBNP, CT-proET-1, MR-proANP, MR-proADM, copeptin and troponin I. Patients were clinically followed-up up to 12 months for first occurrence of hospital admission due to PAH-related clinical worsening, heart/lung transplantation or all-cause mortality. RESULTS: Among the 28 included patients the pre-specified end-point occurred in 8 (29% event rate). There were higher baseline levels of CT-proET-1, copeptin, MR-proANP, NT-proBNP and troponin I in patients who reached the composite end-point. They also had larger right atria. In multivariate Cox regression, CT-proET-1 was the only biomarker associated with increased hazard of reaching the primary composite end-point (hazard ratio per tertile increase = 10.1; 95% CI 2.0 to 50.6). CONCLUSIONS: CT-proET-1 provided prognostic information independent of other biomarkers. Importantly, we have provided the first evidence that CT-proET-1 may be superior to commonly used biomarkers.
BACKGROUND:Pulmonary arterial hypertension (PAH) is a rare, deadly condition. Although risk stratification is extremely important for assessment of prognosis and to guide therapy, there is lack of evidence concerning the role of novel biomarkers. In a pivotal study, we sought to comparatively investigate the predictive power of several new biomarkers in PAH. METHODS:Patients with prevalent PAH were enrolled in the study protocol, which included clinical, functional and echocardiographic assessment. Blood samples were collected at baseline for determination of NT-proBNP, CT-proET-1, MR-proANP, MR-proADM, copeptin and troponin I. Patients were clinically followed-up up to 12 months for first occurrence of hospital admission due to PAH-related clinical worsening, heart/lung transplantation or all-cause mortality. RESULTS: Among the 28 included patients the pre-specified end-point occurred in 8 (29% event rate). There were higher baseline levels of CT-proET-1, copeptin, MR-proANP, NT-proBNP and troponin I in patients who reached the composite end-point. They also had larger right atria. In multivariate Cox regression, CT-proET-1 was the only biomarker associated with increased hazard of reaching the primary composite end-point (hazard ratio per tertile increase = 10.1; 95% CI 2.0 to 50.6). CONCLUSIONS: CT-proET-1 provided prognostic information independent of other biomarkers. Importantly, we have provided the first evidence that CT-proET-1 may be superior to commonly used biomarkers.
Authors: Henrik Ten Freyhaus; Daniel Dumitrescu; Sonja Schnorbach; Kai Kappert; Thomas Viethen; Martin Hellmich; Nicolas Hunzelmann; Stephan Rosenkranz Journal: Clin Res Cardiol Date: 2015-02-24 Impact factor: 5.460
Authors: Neeraj Dhaun; Jale Yuzugulen; Robert A Kimmitt; Elizabeth G Wood; Pajaree Chariyavilaskul; Iain M MacIntyre; Jane Goddard; David J Webb; Roger Corder Journal: J Am Heart Assoc Date: 2015-03-23 Impact factor: 5.501
Authors: Steffen D Kriechbaum; Lillith Scherwitz; Christoph B Wiedenroth; Felix Rudolph; Jan-Sebastian Wolter; Moritz Haas; Ulrich Fischer-Rasokat; Andreas Rolf; Christian W Hamm; Eckhard Mayer; Stefan Guth; Till Keller; Stavros V Konstantinides; Mareike Lankeit; Christoph Liebetrau Journal: ERJ Open Res Date: 2020-11-02
Authors: Marta Banaszkiewicz; Aleksandra Gąsecka; Szymon Darocha; Michał Florczyk; Arkadiusz Pietrasik; Piotr Kędzierski; Michał Piłka; Adam Torbicki; Marcin Kurzyna Journal: J Clin Med Date: 2022-01-13 Impact factor: 4.241